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Abstract
Background: Early relapse in colorectal cancer (CRC) patients is attributed mainly to the higher malignant entity (such as an
unfavorable genotype, deeper tumor invasion, lymph node metastasis and advance cancer stage) and poor response to
chemotherapy. Several investigations have demonstrated that genetic polymorphisms in drug-targeted genes, metabolizing
enzymes, and DNA-repairing enzymes are all strongly correlated with inter-individual differences in the efficacy and toxicity of
many treatment regimens. This preliminary study attempts to identify the correlation between genetic polymorphisms and
clinicopathological features of CRC, and evaluates the relationship between genetic polymorphisms and chemotherapeutic
susceptibility of Taiwanese CRC patients. To our knowledge, this study discusses, for the first time, early cancer relapse and its
indication by multiple genes.
Methods: Six gene polymorphisms functional in drug-metabolism – GSTP1 Ile105Val, ABCB1 Ile1145Ile, MTHFR Ala222Val, TYMS
double (2R) or triple (3R) tandem repeat – and DNA-repair genes – ERCC2 Lys751Gln and XRCC1 Arg399Gln – were assessed
in 201 CRC patients using a polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) technique and
DNA sequencing. Patients were diagnosed as either high-risk stage II (T2 and 3 N0 M0) or III (any T N1 and 2 M0) and were
administered adjuvant chemotherapy regimens that included 5-fluorouracil (5FU) and leucovorin (LV). The correlations between
genetic polymorphisms and patient clinicopathological features and relapses were investigated.
Results: In this study, the distributions of GSTP1 (P = 0.003), ABCB1 (P = 0.001), TYMS (P < 0.0001), ERCC2 (P < 0.0001) and
XRCC1 (P = 0.006) genotypes in the Asian population, with the exception of MTHFR (P = 0.081), differed significantly from their
distributions in a Caucasian population. However, the unfavorable genotype ERCC2 2251A>C (P = 0.006), tumor invasion depth
(P = 0.025), lymph node metastasis (P = 0.011) and cancer stage (P = 0.008) were significantly correlated with early relapse.
Patients carrying the ERCC2 2251AC or2251CC genotypes had a significantly increased risk of early relapse (OR = 3.294, 95%
CI, 1.272–8.532).
Conclusion: We suggest that ERCC2 2251A>C alleles may be genetic predictors of early CRC relapse.
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Background
The primary treatment for colorectal cancer (CRC) is
resection of the primary tumor. After surgery, patients are
frequently administered adjuvant chemotherapy to elimi-
nate cancer cells that may have metastasized [1]. Despite
chemotherapy, CRC remains the third major cause of can-
cer-related death in Taiwan, accounting for >3,000 deaths
per year [2]. The overall five-year survival is 50–60% in
European countries [3], a result similar to that in Taiwan
[4]. The primary cause of death is distant and loco-
regional relapses. Notably, CRC relapse is strongly corre-
lated with chemotherapeutic drug response [1,5,6].
Genetic polymorphisms in drug-targeted genes [7,8],
metabolizing enzymes [9], and DNA-repairing enzymes
[10] have been linked to inter-individual differences in
the efficacy and toxicity of numerous drugs. Several stud-
ies have investigated various gene expressions and chem-
otherapeutic drug responses of cancers. For instance, a
polymorphic 28-bp tandem double repeat polymorphism
in the regulatory region of the TYMS gene is correlated
with a better response to 5-fluorouracil (5 FU) chemother-
apy than the triple repeat in the polymorphism [11]. A
common polymorphism in the MTHFR gene (677C>T;
Ala222Val) increases the efficacy of fluoropyrimidine-
based chemotherapy [12]. In Caucasian patients with
advanced CRC who are treated with oxaliplatin, 5 FU and
leucovorin (LV), ERCC1 118 T/T, XRCC1 (Arg – >Gln sub-
stitution in exon 10), ERCC2 751AC, and ERCC2 751CC
genotypes are independently associated with poor pro-
gression-free survival and short-term survival [13,14].
Glutathione S-transferases (GSTs) participate in the
detoxification of platinum compounds and are important
mediators of intrinsic and acquired resistance to oxalipla-
tin [8].
Advanced CRC is one of the most chemotherapy-resistant
human malignancies. The cytotoxic agent with the most
consistent antitumor activity is 5 FU. However, significant
variability in drug response can occur among cancer
patients treated with the same medications [15]. Elevated
levels of thymidylate synthase (TS) are correlated with
resistance to 5 FU and a poor clinical outcome [16-19].
Conventional regimens for treating cancer patients with
chemotherapy do not account for interpatient variability
in the expression of particular target genes. Such variabil-
ity results in unpredictable tumor responses and host tox-
icity. This hospital-based study investigates the role of
multiple genetic polymorphisms of six metabolizing and
DNA-repair genes (GSTP1, Glutathione S-transferase P1;
ABCB1, multidrug resistance 1; MTHFR, methylenetet-
rahydrofolate reductase; TYMS, thymidylate synthase;
ERCC2, excision repair cross-complementing rodent
repair deficiency, complementation group 2; XRCC1, X-
ray cross-complementing 1) in literature, genomic data-
bases, and the Medline database [10-12,20-23]. The corre-
lations between single nucleotide polymorphisms of the
six candidate genes and clinicopathological features of
201 Taiwanese CRC patients, in addition to the relation-
ship between genetic variants and post-therapy early
relapse, were also analyzed to elucidate the roles of geno-
types of these six genes as predictors of response of CRC
patients following 5 FU/LV chemotherapy. Furthermore,
this study reviewed current literature regarding the distri-
bution of these six candidate genes and their genotypes in
CRC patients of different ethnic groups, and compared
differences between Taiwanese CRC patients and those of
other races.
This is the first investigation of clinical outcome using
multiple chemotherapeutic drug-related genetic polymor-
phisms for Taiwanese patients with advanced CRC. The
ability to predict with a high degree of accuracy which
patients are likely to respond to treatment and those who
are unlikely to respond will significantly influence the
design of new treatment regimens.
Methods
Patients and specimens
Enrolled in this prospective study were 201 Taiwanese
high-risk International Union Against Cancer (UICC)
stage II and stage III CRC patients (median age, 62.09 ±
12.67 years) who were admitted to the Department of
Surgery at Kaohsiung Medical University Hospital for elec-
tive surgery. Patients with other malignant diseases in
their medical history were excluded. All 201 patients
underwent radical resection for a primary lesion. Radical
resection was defined as any gross residual tumor that did
not remain in the surgical bed, and the surgical resection
margin is pathologically negative for tumor invasion. All
patients were diagnosed as either high-risk stage II (T2 and
3 N0 M0) or III (any T N1 and 2 M0). Patients with risk
factors for relapse (tumor poorly differentiated, tumor
perforation, number of lymph nodes examined <12 or
lymphatic/vascular invasion) were considered high-risk
stage II cases. Written informed consent was obtained
from all subjects and/or guardians for use of their blood
samples. The follow-up endpoint was June 2007. Sample
acquisition and subsequent use were approved by the
institutional review board at the Kaohsiung Medical Uni-
versity Hospital. Patients were administered six 8-week
cycles of adjuvant chemotherapy. Each cycle consisted of
leucovorin 500 mg/m2 administered as a 2-h infusion and
given weekly for six doses, and 5 FU 500 mg/m2 adminis-
tered as an intravenous bolus 1 h after the start of leucov-
orin infusion and repeated weekly for 6 doses. This cycle
was then repeated after a 2-week rest period. Postoperative
surveillance consisted of comprised medical history,
physical examination, and laboratory studies, includingBMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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assessing serum carcinoembryonic antigen (CEA) levels at
3-month intervals. Abdominal ultrasonography or com-
puted tomography was performed at 6-month intervals,
and chest radiography, bone scans, and total colonoscopy
were performed annually. Patients were followed up at 3-
month intervals for 2 years and at 6-month intervals
thereafter. Median follow-up time was 34.2 months
(range, 24–40 months). Clinical stage and pathological
features of primary tumors were defined according to cri-
teria of the American Joint Commission on Cancer/Inter-
national Union Against Cancer (AJCC/UICC) [24].
Development of new post-operative recurrent or meta-
static lesions was defined as postoperative relapse. Early
relapse was defined as local recurrence (tumor growth
restricted to the anastomosis or the region of the primary
operation) or distant metastasis (distant metastasis or dif-
fuse peritoneal seeding) within 1 year following radical
resection.
DNA extraction
Constitutional gene polymorphisms were analyzed via
DNA extraction from 4 ml peripheral blood using a PURE-
GENE® DNA Isolation Kit (Gentra Systems, Inc., Minneap-
olis, MN, USA).
PCR-RFLP
All genomic DNA from patients were examined using the
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) approach to determine the
genotypes of GSTP1, ABCB1, MTHFR, TYMS, ERCC2, and
XRCC1. Following digestion with suitable restriction
enzymes, PCR fragments were separated on a 2.5–3.0%
agarose gel and visualized after ethidium bromide stain-
ing. This study also utilized the automated sequencing
approach to confirm PCR-RFLP results (Figs. 1, 2, 3, 4). All
primers utilized in this study were designed by using
Primer3 freeware [25]. Table 1 presents the primer
sequences and restriction enzymes. The PCR reaction vol-
ume was 40 μL. The PCR conditions, for the GSTP1 poly-
morphism were as follows: 95°C for 5 min, 35 cycles at
95°C for 30 s, annealing at 65°C for 10 s, and 72°C for
25 s. A 433-bp product was amplified following digestion
with BsmAI. Digestion generated fragments of 329 and
104 bp for the A allele, and fragments of 222, 107, and
104 bp for the Gallele. The PCR conditions for the ABCB1
polymorphism were as follows: 95°C for 5 min, 35 cycles
at 95°C for 30 s, annealing at 58°C for 15 s, and 72°C for
20 s. A 244-bp product was amplified following digestion
with DpnII. Digestion generated fragments of 172 and 72
bp for the C allele, and a 244-bp fragment for the T allele.
The PCR conditions for the MTHFR polymorphism were
as follows: 95°C for 5 min, 35 cycles at 95°C for 30 s,
annealing at 70°C for 20 s, and 72°C for 25 s. A 400-bp
product was amplified following digestion with HinfI.
Digestion produced a 400-bp fragment for the C allele,
and 318 and 82 bp fragments for the T allele. The PCR
conditions for the TYMS polymorphism were as follows:
95°C for 5 min, 35 cycles at 95°C for 30 s, and 72°C for
35 s. A 240- and 212-bp product was amplified for the 3R
allele and 2R allele, respectively. The PCR conditions for
the ERCC2 polymorphism were as follows: 95°C for 5
min, 35 cycles at 95°C for 30 s, annealing at 64°C for 10
s, and 72°C for 20 s. A 149-bp product was amplified fol-
lowing digestion with PstI. Digestion generated 143- and
6-bp fragments for the A allele, and fragments of 80, 63,
and 6 bp for the C allele. The PCR conditions for the
XRCC1 polymorphism were as follows: 95°C for 5 min,
35 cycles at 95°C for 30 s, annealing at 62°C for 20 s, and
72°C for 20 s. A 208-bp product was amplified following
digestion with MspI. Digestion produced 156- and 52-bp
fragments for the G allele, and a 208-bp fragment for the
A allele.
Statistical analysis
All data were analyzed using the Statistical Package for the
Social Sciences Version 12.0 (SPSS, Inc., Chicago, IL,
USA). The correlation between a polymorphism and
relapse status was assessed using the relative risk ratio and
a 95% confidence interval (CI). This is an exploratory and
Table 1: Characteristics of the studied polymorphisms with primer sequences and restriction enzymes
Gene Primer sequences Restriction enzyme Polymorphism
GSTP1 [F]:G5'-GTAGTTTGCCCAAGGTCAAG-3'
[R]:G5'-AGCCACCTGAGGGGTAAG-3'
BsmAI Ile105Val (313A>G)
ABCB1 [F]:G5'-GATCTGTGAACTCTTGTTTTC-3'
[R]:G5'-GAAGAGAGACTTACATTAGGC-3'
DpnII Ile1145Ile (3435C>T)
MTHFR [F]:G5'-CTTGAACAGGTGGAGGCCAGC-3'
[R]:G5'-AGGACGGTGCGGTGAGAGTG-3'
HinfI Ala222Val (677C>T)
TYMS [F]:G5'-GACCCCGCCGAGCAGGAAGA-3'
[R]:G5'-GTGCCCGTGCGGTCGTCCTT-3'
- 28-bp repeat (5'-UTR)
ERCC2 [F]:G5'-TCTGCAGGAGGATCAGCTG-3'
[R]:G5'-GCAAGACTCAGGAGTCAC-3'
PstI Lys751Gln (2251A>C)
XRCC1 [F]:G5'-TTGTGCTTTCTCTGTGTCCA-3'
[R]:G5'-TCCTCCAGCCTTTTCTGATA-3'
MspI Arg399Gln (1196G>A)BMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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hypothesis-generating study. To clarify the clinical signifi-
cance of these combined genotypes as predictors of post-
operative relapse, a multivariate adjustment was
performed by logistic regression analysis. The two-sided
Pearson χ2 test was applied to assess the differences in dis-
tributions of genotypes between different races. A value of
P < 0.05 was considered statistically significant.
Results
Patient characteristics
In total, 201 patients were enrolled. Of these, 118 were
male (58.7%) and 83 were female (41.3%). Thirty-three
patients (16.4%) were aged : 50 years and 120 (59.7%)
were >60 years (range, 33–75 years). Thirty cases (14.9%)
developed early relapse, either local recurrence or distant
metastasis, during follow-up. Primary tumor location for
146 cases (72.6%) was the colon and 55 (27.4%) was the
rectum. In total, 105 cases (52.2%) were UICC stage II,
and 96 cases (47.8%) were UICC stage III. Table 2 lists the
other clinicopathological characteristics of patients and
tumors.
PCR-RFLP analysis and automated sequencing of GSTP1 A313G Figure 1
PCR-RFLP analysis and automated sequencing of GSTP1 A313G. Figures 1A-C present PCR-RFLP analysis results for 
GSTP1 single nucleotide polymorphisms. The GSTP1 exon5 A313G was restricted by BsmAI. Digestion resulted in 329 and 104 
bp fragments for the A allele, and 222, 107, and 104 bp fragments for the G allele (Fig. 1A: The RFLP of GSTP1 results. Fig. 1B: 
Picture of GSTP1 313AA sequences. Fig. 1C: Picture of GSTP1 313GG sequences)BMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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Correlation between early relapse and clinicopathological 
data
No statistical correlations existed between early relapse
status and sex, age, tumor size, tumor location and histol-
ogy (P > 0.05; Table 2). However, depth of tumor inva-
sion, lymph node metastasis and cancer stage were
significantly related to early relapse (P < 0.05). Risk of
early relapse was higher in T3+T4 that had a deeper inva-
sion than did T2 (OR, 1.205; 95% CI, 1.127–1.289; P =
0.025). Stage III patients had a higher early relapse rate
than stage II patients (OR, 2.897; 95% CI, 1.243–6.381; P
= 0.011), and early relapse was higher in cases with lymph
node metastasis than those with no lymph node metasta-
sis (OR, 2.987; 95% CI, 1.293–6.899; P = 0.008).
Comparison of genotype distributions between Taiwanese 
CRC patients and those of other races
To compare the genotypes of Taiwanese CRC patients
with those of other races (Table 3), this study compared
the distribution of gene polymorphisms, such as GSTP1
313A>G (AA, AG, GG), ABCB1 3435C>T (CC, CT, TT),
MTHFR  677C>T (CC, CT, TT), TYMS  tandem repeat
(3R3R, 2R3R, 2R2R), ERCC2 2251A>C (AA, AC, CC) and
XRCC1 1196G>A (GG, GA, AA), in various races, races –
PCR-RFLP analysis and automated sequencing of MTHFR C667T Figure 2
PCR-RFLP analysis and automated sequencing of MTHFR C667T. Figures 2A-C present PCR-RFLP analysis results for 
MTHFR single nucleotide polymorphisms. Notably, MTHFR was restricted by HinfI. Digestion resulted in a 400-bp fragment for 
the C allele, and 318 and 82 bp fragments for the T allele. (Fig. 2A: Results for RFLP of MTHFR. Fig. 2B: Picture of MTHFR 
677CC sequences. Fig. 2C: Picture of MTHFR 677TT sequences)BMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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Caucasian, Japanese, Korean, Chinese, and Taiwanese.
This study also included our findings from a literature
review.
For GSTP1, 129 (64.2%) were AA, 66 (32.8%) were AG
and 6 (3.0%) were GG genotype carriers, as compared
with Caucasians [26] (AA, 42%; AG, 47.4%; GG, 10.6%)
and Taiwanese [27] (AA, 67.9%; AG, 28.7%; GG, 3.4%).
The distribution of GSTP1 313A>G genotypes in our data
differed significantly from that of Caucasian patients (P =
0.003); however, no significant differences existed when
compared with previous Taiwanese studies (P = 0.827).
For ABCB1, 70 (34.8%) were CC, 104 (51.8%) were CT
and 27 (13.4%) were TT genotype carriers, as compared
with Caucasians [28] (CC, 22.3%; CT, 44%; TT, 33.7%),
Japanese [29] (CC, 29.2%; CT, 58.3%; TT, 12.5%) and
Korean [30] (CC, 28.8%; CT, 56.8%; TT, 14.4%). The dis-
tribution of ABCB1 3435C>T genotypes was significantly
different from that in Caucasians (P = 0.001) and not sig-
PCR-RFLP analysis and automated sequencing of ERCC2 A2251C Figure 3
PCR-RFLP analysis and automated sequencing of ERCC2 A2251C. Figures 3A-C present PCR-RFLP analysis results 
for ERCC2 single nucleotide polymorphisms. Notably, ERCC2 was restricted by MspI. Digestion resulted in 143 and 6 bp frag-
ments for the A allele, and 80, 63, and 6 bp fragments for the C allele. (Fig. 3A: Result for RFLP of ERCC2. Fig. 3B: Picture of 
ERCC2 2251AA sequences. Fig. 3C: Picture of ERCC2 2251CC sequences)BMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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nificantly different from that in Japanese (P = 0.641), and
Korean populations (P = 0.661).
For MTHFR, 122 (60.7%) were CC, 72 (35.8%) were CT
and 7 (3.5%) were TT genotype carriers, as compared with
Caucasians [31] (CC, 46%; CT, 45%; TT, 9%), Japanese
[32] (CC, 39.4%; CT, 48.2%; TT, 12.4%), and Korean [33]
(CC, 35.4%; CT, 50.2%; TT, 14.4%) populations. Signifi-
cantly different distributions of MTHFR 677C>T (CC, CT,
TT) genotypes existed when our data was compared with
Japanese (P = 0.005) or Korean data (P = 0.001), and it
does not significantly different from Caucasian data (P =
0.081).
For TYMS, 135 (67.2%) were 3R/3R, 59 (29.3%) were 2R/
3R, and 7 (3.5%) were 2R/2R genotype carriers, as com-
pared with Caucasians (3R/3R, 32%; 3R/2R, 50%; 2R/2R,
18%), Japanese [34] (3R/3R, 69%; 3R/2R, 27%; 2R/2R,
4%), and Chinese [35] (3R/3R, 67%; 3R/2R, 31%; 2R/2R,
2%) populations. The highest expression of TYMS 3R/3R
in this study of Taiwanese patients was similar to that of
Japanese (P  = 0.951) and Chinese populations (P  =
0.693), but different from that of the Caucasian popula-
tion [36] (P < 0.0001).
For ERCC2, 176 (87.6%) were AA, 24 (11.9%) were AC,
and 1(0.5%) were CC genotype carriers, as compared with
Caucasians [37] (AA, 25%; AC, 61%; CC, 14%) and Tai-
wanese [38] (AA, 84%; AC, 15.6%; CC, 0.4%) popula-
tions. The highest expression of ERCC2 AA in this study
was similar to that in a previous study [38] (P = 0.436)
and different from that of a Caucasian population (P <
0.0001). Caucasian CRC cancer patients presented with
ERCC2 AC as the most common polymorphism geno-
type. In this study and another previous Taiwanese stud-
ies, ERCC2 2251A>C AA was more common than AC and
CC, while another study indicated that ERCC2 2251A>C
AC was the most frequent genotype.
For XRCC1, 124 (61.7%) were GG, 64 (31.8%) were GA
and 13 (6.5%) were AA genotype carriers, as compared
with Caucasian [37] (GG, 39%; GA, 52%; AA, 9%),
Korean [39] (GG, 53.6%; GA, 42.1%; AA, 4.3%), and Tai-
wanese [38] (GG, 56.7%; GA, 36.2%; AA, 7.1%) popula-
tions. The highest expression of XRCC1 GG in this study
was similar to that for Koreans (P = 0.257) and other Tai-
wanese studies (P = 0.802), but different from that of the
Caucasian population (P = 0.006).
Correlation between genetic polymorphisms with 
clinicopathological data
This study assessed correlations between genetic polymor-
phisms and clinicopathological features of 201 Taiwanese
CRC patients (Table 4). No statistically significant correla-
tions existed between genotype distributions and sex, age,
tumor site or location, depth of tumor invasion, lymph
node metastasis, cancer stage, or histology (all P > 0.05).
Correlation between early relapse and genetic 
polymorphisms
The correlations between gene polymorphisms (GSTP1
313A>G, ABCB1 3435C>T, MTHFR 667C>T, TYMS dou-
ble or triple tandem repeats, ERCC2 2251A>C and XRCC1
1196G>A) and patients with or without early recurrence
were examined. Statistical analyses indicate that genotype
polymorphisms of ERCC2  were strongly correlated
between patients with recurrent and non-recurrent tumors
(P = 0.006; Table 5); however, GSTP1, ABCB1, MTHFR,
TYMS, and XRCC1 genotypes polymorphisms were not
correlated (P  > 0.05; Table 5). The Taiwanese CRC
patients with ERCC2 2251AC and ERCC2 2251CC geno-
types have a risk of recurrence 3.294 times greater than
that of those with other genotypes (P = 0.01; 95% CI,
1.272–8.532).
Discussion
This is an exploratory and hypothesis-generating study.
This study attempted to move beyond single genetic poly-
morphisms to a more comprehensive investigation that
identifies genomic variants and patterns and performed
PCR-RFLP analysis of TYMS repeat polymorphisms Figure 4
PCR-RFLP analysis of TYMS repeat polymorphisms. 
Figure 4 presents PCR-RFLP analysis results for TYMS repeat 
polymorphisms. A 240-bp product was amplified for the 3R 
allele and a 212-bp product was amplified for the 2R allele.BMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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early relapse analysis. This study investigated six func-
tional genomic polymorphisms in genes, which have dif-
ferent enzyme functions, or expressions, and DNA repair
by PCR-RFLP assay and cycling sequencing. This is the first
comprehensive study to investigate genotype frequencies
of six gene polymorphisms in Taiwanese CRC patients.
Additionally, this study analyzed the genotypes of 201
Taiwanese CRC patients and demonstrated that genotype
distributions have ethnic variations.
In 5FU-related genes, the incidence of the TYMS gene pro-
moter 3R/3R genotype in the 201 cases in this study is
similar to that in Japanese [34] and Chinese [35] popula-
tions, and higher than that in Caucasian populations [36].
Neither the TYMS 2R allele nor the TYMS 3R allele is pre-
dominant in Caucasians; however, the TYMS 3R allele is
predominant in Asian populations. For the MTHFR
C677T polymorphism, the incidence of the 677CC geno-
type in this Taiwanese CRC population was higher than
that for Caucasians [31], and Japanese [32], and Korean
[33] populations (Table 3). Notably, the C allele and T
allele frequencies in Caucasian and Asian populations are
similar.
This study assessed the ABCB1 3435C>T of 201 Taiwanese
CRC patients. The frequency of the TT genotype in the 201
Taiwanese patients is similar to that in Japanese [29] and
Korean [30] patients, but lower than that in Caucasian
populations [28]. The allele frequency of C and T did not
differ between Caucasians and Asians.
The genotype data for cell detoxification-related gene pol-
ymorphism, GSTP1 313A>G, are similar to that for 408
Taiwanese CRC patients in a study by Yen et al. [27]. Cau-
casian populations have an equal incidence of AA
homozygotes and AG heterozygotes [26]; however, the
Taiwanese population has more AA homozygotes than
AG heterozygotes. The allele frequency of Ile is also more
predominant in Taiwanese patients than in Caucasian
patients.
Since the genetic polymorphisms of DNA-repair enzymes
may influence DNA adduct levels [40-42], the particular
degree of DNA repair capacity can be utilized to identify
genetically high-risk individuals for human cancers [43].
Resistance to platinum agents has been attributed to
increased tolerance to platinum DNA adducts, enhanced
DNA repair, or decreased drug accumulation [44]. Pro-
teins of the nucleotide excision repair (NER) pathway, in
particular, are believed play a central role in repair of DNA
damage caused by platinum compounds. The enzymes
related to the DNA repair system, XRCC1  and ERCC2,
were similar to those identified in other studies of Taiwan-
ese CRC patients [38]. Although very few studies have
Table 2: Correlations between clinicopathological features and recurrence status for 201 postoperative colorectal cancer patients
Characteristics Total cases N (%) Early recurrence N (%) Non-early recurrence N (%) P
Gender
Male 118 (58.7) 17 (56.7) 101 (59.1) 0.806
Female 83 (41.3) 13 (43.3) 70 (40.9)
Age (years)
>60 120 (59.7) 23 (76.7) 97 (56.7) 0.105
51~60 48 (23.9) 5 (16.7) 43 (25.1)
 50 33 (16.4) 2 (6.6) 31 (18.2)
Tumor Size
<5 cm 107 (53.2) 16 (53.3) 91 (53.2) 0.991
 5 cm 94 (46.8) 14 (46.7) 80 (46.8)
Location
Colon 146 (72.6) 22 (73.3) 124 (72.5) 0.926
Rectum 55 (27.4) 8 (27.7) 47 (27.5)
Depth of tumor invasion
T2 26 (12.9) 0 (0) 25 (14.6) 0.025
T3 + T4 175 (87.1) 30 (100) 146 (85.4)
Lymph node metastasis
Negative 110 (54.7) 10 (33.3) 100 (58.5) 0.011
Positive 91 (45.3) 20 (66.7) 71 (41.5)
Stage (UICC)a
II 105 (52.2) 9 (30) 96 (56.1) 0.008
III 96 (47.8) 21 (70) 75 (43.9)
Histology
Well + moderately differentiated 170 (84.6) 23 (76.7) 147 (86) 0.193
Poorly differentiated 31 (15.4) 7 (23.3) 24 (14)
aInternational Union Against CancerBMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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investigated these two polymorphisms in Asian CRC pop-
ulations, the incidence of XRCC1 G1196A in a Korean
population [39] is similar to that in the 201 Taiwanese
patients in this study. However, the frequency of the
XRCC1 GG homozygous and GA heterozygous patients in
Caucasian [37] and Asian populations differ significantly.
Moreover, the frequency of the G allele and A alleles do
not differ between Caucasians and Asians. For ERCC2
2251A>C, the genotype and allele frequencies are dissim-
ilar between Taiwanese and Caucasians [37]. Neither the
A allele nor C allele has been identified as predominant in
Caucasians, whereas the A allele is predominant in the
Taiwanese (Table 3).
In 2004, Shirao et al. compared the efficacy, toxicities, and
pharmacokinetics of an oral regimen consisting of uracil/
tegafur (UFT) and LV between Japanese patients and Cau-
casian patients in the United States [45]. Although the
response rate did not differ (36.4% for Japanese patients
and 34.1% for patients in the United States), a difference
existed in toxicity profile, specifically the incidence of
diarrhea – 9% in the Japanese population and 22% in the
Caucasian population in the United States. Since geno-
type frequencies were similar between Japanese and Tai-
wanese populations, we suggest that cancer chemotherapy
efficacy, toxicities, and pharmacokinetics would be simi-
lar to those for Japanese patients. Consequently, we
hypothesize that these polymorphisms screened have the
ability to predict toxicity, clinical outcome and survival in
Taiwanese CRC patients. This hypothesis and suggestion
warrant further investigation.
Table 3: Comparison of genotype and allele frequencies (%) between Taiwanese colorectal cancer patients and those of other ethnic 
groups
Genotype Caucasian Japanese Korean Chinese Taiwanese Study data
GSTP1 Van der Logt26 Yeh27
AA 42.0 - - - 67.9 64.2
AG 47.4 - - - 28.7 32.8
GG 10.6 - - - 3.4 3.0
A allele 0.657 - - - 0.823 0.807
G allele 0.343 - - - 0.177 0.193
ABCB1 Kurzawski28 Komoto29 Bae30
CC 22.3 29.2 28.8 - - 34.8
CT 44 58.3 56.8 - - 51.8
TT 33.7 12.5 14.4 - - 13.4
C allele 0.443 0.584 0.572 - - 0.607
T allele 0.557 0.416 0.428 - - 0.393
MTHFR Curtin31 Yin32 Kim33
CC 46 39.4 35.4 - - 60.7
CT 45 48.2 50.2 - - 35.8
TT 9 12.4 14.4 - - 3.5
C allele 0.685 0.635 0.605 - - 0.786
T allele 0.315 0.365 0.395 - - 0.214
TYMS Chen36 Kawakami34 Marsh35
3R/3R 32 69 - 67 - 67.2
2R/3R 50 27 - 31 - 29.3
2R/2R 18 4 - 2 - 3.5
3R allele 0.570 0.825 - 0.825 - 0.818
2R allele 0.430 0.175 - 0.175 - 0.182
ERCC2 Stoehlmacher37 Yeh38
AA 25 - - - 84 87.6
AC 61 - - - 15.6 11.9
CC 14 - - - 0.4 0.5
A allele 0.555 - - - 0.918 0.935
C allele 0.445 - - - 0.082 0.065
XRCC1 Stoehlmacher37 Hong39 Yeh38
GG 39 - 53.6 - 56.7 61.7
GA 52 - 42.1 - 36.2 31.8
AA 9 - 4.3 - 7.1 6.5
G allele 0.650 - 0.747 - 0.748 0.776
A allele 0.350 - 0.253 - 0.252 0.224
NOTE: authorn in this table is designated by a reference number (n) and the abbreviated name of the first author in the previously paper.BMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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Studies focusing on acute relapse risk of CRC and these
metabolizing and DNA-repair genes are limited and con-
troversial. In addition to the statistically significant role of
early relapse, including depth of tumor invasion (P  =
0.025), lymph node metastasis (P = 0.011), and cancer
stage (P = 0.008), analytical results in this study indicate
ERCC2 2251A>C AC and CC gene polymorphismswere
statistically significant in predicting early relapse.
The DNA repair systems play an important role in main-
taining genomic integrity and preventing carcinogenesis
[46]. At least four pathways for DNA repair operate on
specific DNA damage types [47]. Nucleotide excision
repair is the primary pathway in humans. The ERCC2 gene
plays a dominant role in nucleotide excision repair and
basal transcription, both of which are crucial to the elim-
ination of bulky DNA adducts. Furthermore, the ERCC2
protein is essential for nucleotide excision repair activity
[48,49]. The ERCC2 gene consists of 23 exons at 19q13.3.
Several single nucleotide polymorphisms have been iden-
tified in the coding part of ERCC2, of which Ile199Met (C/
G), His201Tyr (C/T), Asp312Asn (G/A), and Lys751Gln
(A/C) result in amino acid changes; however, codon
Arg156Arg (C/A) and Asp711Asp (C/T) are silent poly-
morphisms. The functional effect of ERCC2  polymor-
phisms remains unclear. The polymorphisms at codon
312 and 751 have been analyzed extensively for their
potential ability to increase lung cancer risk [49,50].
Although an earlier study showed that ERCC2
homozygous variant individuals were at increased risk of
adenomatous polyps [51], associations between DNA
repair gene polymorphisms and CRC have not been
explored extensively. This study suggests that CRC
patients who have the ERCC2 2251AC (751Lys/Gln) or
2251CC (751Glu/Gln) genotypes have a significantly
increased early relapse risk (OR = 3.294; 95% CI,
1.272–8.532), and no statistically significant correlation
exists between genotype distributions and clinicopatho-
logical features (all P > 0.05).
This study examined potential genetic predictors of CRC
relapse. A recent study [52] determined that the C(Glu)
Table 4: Correlation between gene polymorphism and clinicopathological properties of 201 postoperative colorectal cancer patients
GSTP1 ABCB1 MTHFR TYMS ERCC2 XRCC1
Characteristics Total cases (n) AA AG or GG CC CT or TT CC CT or TT 3R3R 2R3R or 2R2R AA AC or CC GG GA or AA
Gender
Male 118 73 45 46 72 68 50 79 39 102 16 73 45
Female 83 56 27 24 59 54 29 56 27 74 9 51 32
P = 0.414 P = 0.140 P = 0.228 P = 0.938 P = 0.566 P = 0.952
Age (yr)
>60 120 76 44 39 81 76 44 80 40 102 18 74 46
5 1 ~ 6 0 4 8 2 82 0 2 02 8 2 72 1 3 2 1 6 4 26 3 31 5
≤50 33 25 8 11 22 19 14 23 10 32 1 17 16
P = 0.293 P = 0.520 P = 0.643 P = 0.944 P = 0.182 P = 0.293
Tumor Size
< 5  c m 1 0 7 6 74 0 3 77 0 6 74 0 7 2 3 5 9 41 3 7 13 6
≥5 cm 94 62 32 33 61 55 39 63 31 82 12 53 41
P = 0.622 P = 0.938 P = 0.552 P = 0.968 P = 0.895 P = 0.147
Location
Colon 146 96 50 52 94 86 60 96 50 127 19 89 57
Rectum 55 33 22 18 37 36 19 39 16 49 6 35 20
P = 0.448 P = 0.701 P = 0.397 P = 0.488 P = 0.687 P = 0.728
Depth of 
tumor invasion
T2 26 19 7 9 17 15 11 17 9 22 4 18 8
T3 + T4 175 110 65 61 114 107 68 118 57 154 21 106 69
P = 0.311 P = 0.981 P = 0.737 P = 0.836 P = 0.626 P = 0.397
Lymph node 
metastasis
N e g a t i v e 1 1 0 6 84 2 4 16 9 6 54 5 7 5 3 5 9 51 5 6 64 4
Positive 91 61 30 29 62 57 34 60 31 81 10 58 33
P = 0.443 P = 0.423 P = 0.608 P = 0.736 P = 0.571 P = 0.588
Stagea
I I 1 0 5 6 44 1 4 16 4 6 24 3 7 1 3 4 9 11 4 6 34 2
III 96 65 31 29 67 60 36 64 32 85 11 61 35
P = 0.318 P = 0.189 P = 0.617 P = 0.886 P = 0.687 P = 0.606
aInternational Union Against CancerBMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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allele of the ERCC2 Lys751Gln variant allele marginally
increased lung cancer risk (OR = 3.61, P = 0.04) in a Chi-
nese population, and another identified [53] increased
risk for squamous cell carcinoma of the head and neck in
patients with the Gln/Gln genotype when compared with
the Lys/Lys group. Experimental results in this study indi-
cate that the ERCC2 2251A>C AC and CC gene polymor-
phisms can predict early relapse; these experimental
results are in agreement with the risk role of the C (Glu)
allele of ERCC2 Lys751Gln in early relapse. Inherited sin-
gle nucleotide polymorphisms of DNA repair genes may
contribute to variations in DNA repair capacity and sus-
ceptibility to cancer. The molecular functional effect of
ERCC2 polymorphisms remains unclear. Although some
researchers have identified incomplete repair of DNA
damage or of aromatic DNA adducts in the presence of
ERCC2 variant alleles [42,54-58], we hypothesize that the
malignant entity of the C (Glu) allele of ERCC2
Lys751Gln is responsible for poor prognosis of early
relapse among CRC patients receiving similar chemother-
apeutic regimens in this study. In 2001, Park reported the
finding of a significant relationship between clinical
response to chemotherapy (combined oxaliplatin and
5FU) and ERCC2 Lys751Gln polymorphisms. Patients
with the Gln/Gln genotype had significantly shorter sur-
vival or increased relative risk of dying when compared
with the Lys/Lys group [10]. These experimental results
suggest that ERCC2 2251A>C may indeed be of functional
importance in Taiwanese CRC. Aggressive chemotherapy
or combined radiotherapy will be considered for patients
with this poor prognostic genotype.
Conclusion
In conclusion, analytical data in this study suggest that the
polymorphism ERCC2 A2251C is associated with risk of
CRC early relapse in a Taiwanese population. Addition-
ally, this study analyzed six gene polymorphisms associ-
ated with the clinical outcome of Taiwanese CRC patients.
These genotypic frequencies vary among ethnic groups.
Studies with relatively larger sample sizes are needed to
elucidate the effects of these polymorphisms on early
relapse risk in this population. However, experimental
results in this study serve as a basis for large-scale correla-
tional studies on the relevance of these variants in predict-
ing early relapse of CRC in a Taiwanese population.
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Table 5: Distribution of gene polymorphisms in 201 colorectal cancer patients and regarding the status of recurrence after surgery
Genotype Total cases N (%) Early Recurrence N (%) Non-early recurrence N (%) P
GSTP1 Ile105Val (313A>G)
AA 129 (64.2) 19 (63.4) 110 (64.3) 0.990
AG 66 (32.8) 10 (33.3) 56 (32.7)
GG 6 (3.0) 1 (3.3) 5 (3)
ABCB1 Ile1145Ile (3435C>T)
CC 70 (34.8) 10 (33.3) 60 (35.1) 0.853
CT 104 (51.8) 15 (50) 89 (52)
TT 27 (13.4) 5 (16.7) 22 (12.9)
MTHFR Ala222Val (677C>T)
CC 122 (60.7) 18 (60) 104 (60.8) 0.994
CT 72 (35.8) 11 (36.7) 61 (35.7)
TT 7 (3.5) 1 (3.3) 6 (3.5)
TYMS double (2R) or triple (3R) tandem repeat
3R/3R 135 (67.2) 20 (66.7) 115 (67.2) 0.492
2R/3R 59 (29.3) 10 (33.3) 49 (28.7)
2R/2R 7 (3.5) 0 (0) 7 (4.1)
ERCC2 Lys751Gln(2251A>C)
AA 176 (87.6) 22 (73.4) 154 (90.1) 0.006
AC 24 (11.9) 7 (23.3) 17 (9.9)
CC 1 (0.5) 1 (3.3) 0 (0)
XRCC1 Arg399Gln(1196G>A)
GG 124 (61.7) 17 (56.7) 107 (62.6) 0.654
GA 64 (31.8) 10 (33.3) 54 (31.6)
AA 13 (6.5) 3 (10) 10 (5.8)BMC Cancer 2008, 8:50 http://www.biomedcentral.com/1471-2407/8/50
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